Jaguar Health, Inc.
(JAGX)
Add Watchlist
0.26 USD -0.01
Closed: 17 May, 3:55 pm
Symbol JAGX
Market Cap 74.2M
Price 0.26
Open 0.27
52-wk High 0.75
50 Day Avg 0.15
Earnings Announcement 2024-08-12
Website https://jaguar.health
Name Jaguar Health, Inc.
Shares Outstanding 287,224,000
Change % -9.8361%
Low 0.26
52-wk Low 0.05
200 Day Avg 0.24
Last Dividend 0.00
Exchange NASDAQ
Volume 22,556,110
Previous Close 0.29
High 0.28
EPS 0.54
PE 0.48
Avg Volume 71,902,217
CUSIP 47010C607
Jaguar Health, Inc. Outlook
Description Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Currency USD
ISIN US47010C7065
Industry Biotechnology
Changes -0.03
CUSIP 47010C607
Range 0.05 - 0.75
Beta 0.90
CIK 0001585608

Jaguar Health, Inc. News

17-May-2024 4:15 PM

Jaguar Health, Inc. Announces Reverse Stock Split

Reverse split approved at April 2024 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on May 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-60, on Thursday, May 23, 2024 (the "Effective Date") in order to support the Company's compliance with Nasdaq's listing standards. The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol "JAGX".

14-May-2024 8:00 AM

Jaguar Health Reports First Quarter 2024 Financial Results

The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased approximately 4% versus net Q4 2023 revenue of $2.3 million Top line results expected to be imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription product REMINDER: Jaguar to host investor webcast Tuesday, May 14th at 8:30 a.m. Eastern regarding Q1 2024 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / May 14, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated first-quarter 2024 financial results and provided Company updates.

13-May-2024 12:35 PM

REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates

Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that the company will conduct an investor webcast on Tuesday, May 14, 2024 at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate updates.

09-May-2024 10:35 AM

Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe

Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBS SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family companies Napo Pharmaceuticals ("Napo") and Napo Therapeutics have submitted a Clinical Trial Application (CTA) to the Italian and German health authorities to initiate a phase 2 clinical trial of Jaguar's novel plant-based prescription drug crofelemer for treatment of short bowel syndrome (SBS) with intestinal failure in adults. Napo Therapeutics has also submitted a CTA to AIFA, the Italian health authority, for the conduct of a clinical trial in pediatric patients with microvillus inclusion disease (MVID), and the approval request process is also underway for this trial in the United Arab Emirates with Dubai Health.

08-May-2024 8:30 AM

Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates

Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Tuesday, May 14, 2024, at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate updates.

07-May-2024 12:31 PM

Want $10,000? Invest $1,000 in These 3 Penny Stocks Now

There's the age-old adage, “You have to spend money to make money.” But then again, what if you could spend pennies and get back dollars?

06-May-2024 8:30 AM

Crofelemer, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company's Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved anti-secretory agents to treat canine diarrhea SAN FRANCISCO, CA / ACCESSWIRE / May 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has established a new Investigational New Animal Drug (INAD) file with the Center for Veterinary Medicine (CVM) of the U.S. Food and Drug Administration (FDA) for the company's novel plant-based prescription drug crofelemer to treat general, non-infectious diarrhea in dogs. Crofelemer delayed-release tablets, under the name Canalevia®-CA1, received conditional approval in December 2021 from the FDA for the treatment of chemotherapy-induced diarrhea (CID) in dogs.

03-May-2024 8:38 AM

Here are the moves to make to counter range-bound, choppy markets, says Goldman Sachs

Friday stock-index futures are looking chipper, given an extra boost by a nonfarm payrolls report that pointed to a cooling labor market and lower wage inflation.

01-May-2024 6:14 AM

Investing in Tech Penny Stocks Right Now, 3 Tips

Investing in tech penny stocks presents an exciting opportunity for investors looking to expand their portfolios with potentially high-reward options. Penny stocks are typically shares of small companies traded at low prices, often under $5.

29-Apr-2024 8:30 AM

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)

Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome (SBS) with intestinal failure Proof-of-concept studies of crofelemer for MVID and SBS planned for 2024 SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2024 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is a Bronze Sponsor of the 10th Annual Elite Ped-GI Congress, which takes place May 2-4, 2024 in Abu Dhabi in the United Arab Emirates (UAE). Additionally, at the conference Napo is sponsoring a panel discussion titled "Masterclass in Congenital Diarrhea" which will focus on microvillus inclusion disease (MVID), an ultra-rare congenital diarrheal disorder.

23-Apr-2024 6:37 AM

3 Obstacles Investors Face When Buying Penny Stocks

Penny stocks represent a unique opportunity for investors aiming to expand their portfolios without a significant initial investment. Trading penny stocks can yield high returns due to their low purchase price, making them an appealing option for both seasoned traders and newcomers to the stock market.